Assertio (ASRT) to Release Quarterly Earnings on Wednesday

Key Points

• Assertio Holdings is set to announce its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.06) per share and revenue of $27.86 million.
• In its last earnings report, Assertio reported a loss of ($0.14) EPS and revenues of $26.49 million, which were below analyst expectations.
• Following recent analyst ratings, Assertio received a buy rating from Alliance Global Partners but was downgraded to a sell rating by Wall Street Zen.

Assertio (NASDAQ:ASRT - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Assertio to post earnings of ($0.06) per share and revenue of $27.86 million for the quarter.

Assertio (NASDAQ:ASRT - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.08). Assertio had a negative net margin of 25.72% and a negative return on equity of 24.87%. The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $27.52 million. During the same quarter in the previous year, the business earned $0.04 EPS. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Assertio Stock Performance

Assertio stock traded down $0.00 during midday trading on Friday, reaching $0.71. 135,077 shares of the company's stock were exchanged, compared to its average volume of 236,412. Assertio has a 52 week low of $0.51 and a 52 week high of $1.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.35 and a current ratio of 1.66. The firm has a market cap of $68.24 million, a price-to-earnings ratio of -2.23 and a beta of 0.28. The stock's 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.70.

Analysts Set New Price Targets

A number of equities analysts recently commented on ASRT shares. HC Wainwright reiterated a "buy" rating and set a $3.50 price target on shares of Assertio in a report on Monday, May 19th. Alliance Global Partners reiterated a "buy" rating on shares of Assertio in a report on Tuesday, May 13th. Finally, Wall Street Zen downgraded shares of Assertio from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.